Navigating treatment strategies for patients with multi-refractory CLL: CAR-T, ASCT, and PI3K Inhibitors

Panelists discuss how various additional treatment options for relapsed/refractory chronic lymphocytic leukemia (CLL) are considered, including CAR-T cell therapy, immunomodulatory drugs like lenalidomide, chemoimmunotherapy regimens, and other emerging therapies, highlighting their potential roles in the evolving treatment landscape.

EP: 1.The Current Treatment Landscape for R/R CLL

EP: 2.Impact of Prior BTKi vs BCL2i Therapy on Treatment Decision-Making in CLL

EP: 3.Key Patient-Specific Factors Guiding Treatment Selection in CLL

EP: 4.Tailoring Treatment Approaches for Rapid vs. Slow Disease Progression in CLL

EP: 5.Assessing Resistance to First-Line BTK Inhibitor Therapy: The Emergine Role of Testing in CLL

EP: 6.Pirtobrutinib in the Management of R/R CLL: Updates from the BRUIN Trial

EP: 7.Application of Pirtobrutinib in R/R CLL: Expert Perspectives

EP: 8.Influence of TLS Risk and Patient Preferences on Treatment Selection in Relapsed/Refractory CLL

Now Viewing

EP: 9.Navigating treatment strategies for patients with multi-refractory CLL: CAR-T, ASCT, and PI3K Inhibitors

EP: 10.Sequencing and Combination Strategies with Pirtobrutinib and CAR-T Therapy in R/R CLL

EP: 11.Treatment Sequencing in Relapsed/Refractory CLL: Key Factors Influencing Decision-Making

EP: 12.Emerging role of doublet triplet therapies in R/R CLL: Expert Perspectives

EP: 13.The Impact of Emerging Resistance Patterns on Treatment Sequencing in R/R CLL

EP: 14.Multidisciplinary Approach to Managing Treatment for Relapsed/Refractory CLL

Video content above is prompted by the following:

• Briefly mention additional treatment options in R/R CLL:
  • CAR-T
  • Duvelisib
  • Idelalisib ± Rituximab
  • Lenalidomide ± Rituximab
  • FCR/BR (if no TP53 or del(17p))
  • HSCT
  • Others?

Related Videos